Faster, better, together: Biopharma collaboration trends in the pandemic, and the future of medicine
The strategic collaborations born out of the efforts to help address the COVID-19 pandemic have offered a wealth of insight into how the biopharma industry will continue to change in the years to come. Companies across the supply chain - from raw materials and technology suppliers to biomanufacturers - view collaboration as a critical strategy to advancing biologics research, scale-up and manufacturing for all biologics development.
Watch Avantor´s and C&EN´s webinar featuring Avantor subject matter experts and guest industry speakers, discussing the benefits of partnership and collaboration.
This webinar event, hosted by C&EN, took place October 27, 2021
|Justin Moran, PhD, Executive Director, Head of Early Bioprocess Development, Pfizer Vaccines
The Impact of a Pandemic on Process Development
|Nandu Deorkar, PhD, Vice President, R&D - Bioprocessing, Avantor
A collaborative ecosystem to accelerate the commercial manufacturing of novel vaccines and other therapeutics
|Jennifer Grossman, PhD, Business Development Manager, Pilot Bioproduction Facility, Walter Reed Army Institute of Research
Lessons on flexibility and scaling-up fast: how the biopharmaceutical industry is preparing to face the next pandemic
|Claudia Berrón, MBA, Senior Vice President, Avantor Clinical Services, Avantor
The impact of decentralization and digitization on clinical trial logistics, kits, and sample management
|Pranav Vengsarkar, PhD, Manager, Process Development, Research Biopharma Production, Avantor
Enhanced raw material delivery strategies: Debottlenecking of buffer and media preparation in mAbs and novel therapeutics